Immunogen Inc $ 8.75 -0.03 (-0.34%)
Volume:
1,643,190
Avg Vol (1m):
2,783,122
Market Cap $:
1.70 Bil
Enterprise Value $:
1.54 Bil
PE Ratio:
0.00
PB Ratio:
18.66
Financial Strength | 4/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | No Debt | ||
Equity-to-Asset | 0.25 | ||
Debt-to-EBITDA | -1.26 | ||
Piotroski F-Score | 4 | ||
Altman Z-Score | -3.88 | ||
Beneish M-Score | 33.88 | ||
WACC vs ROIC |
Profitability Rank | 1/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Operating Margin % | -15.79 | ||
Net Margin % | -33.54 | ||
ROA % | -15.77 | ||
ROC (Joel Greenblatt) % | -96.49 | ||
3-Year Revenue Growth Rate | -7 | ||
3-Year EBITDA Growth Rate | 25.8 | ||
3-Year EPS without NRI Growth Rate | 25.2 |
IMGN
Valuation Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
PB Ratio | 18.66 | ||
PS Ratio | 12.17 | ||
EV-to-EBIT | -72.75 | ||
EV-to-EBITDA | -78.58 | ||
EV-to-Revenue | 11.64 | ||
Current Ratio | 2.4 | ||
Quick Ratio | 2.4 | ||
Days Sales Outstanding | 13.93 | ||
Days Payable | 28.39 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
3-Year Average Share Buyback Ratio | -19.9 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Tangible-Book | 18.62 | ||
Price-to-Median-PS-Value | 1.26 | ||
Earnings Yield (Greenblatt) % | -1.37 |